|
Tanking of First Bapineuzumab Trial Expected, Small Flicker of Hope for Other Pfizer/J&J Studies: Analysts
The inability of Pfizer, Johnson & Johnson and Elan’s Alzheimer’s treatment bapineuzumab to disprove low expectations with its first set of late-stage trial data has pharma analysts even more wary that other studies of the drug will pan out.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives